Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 9022 results

  1. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]

    In development Reference number: GID-TA11768 Expected publication date:  28 October 2026

    Technology appraisal guidance
    In development

  3. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Electrocautery cutting balloon treatment for pelviureteric junction obstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Cor-Knot for tying suture knots in valve surgery

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Awaiting development Reference number: GID-TA11956 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]

    Awaiting development Reference number: GID-TA11465 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Bioinductive collagen scaffold (Regeneten) for rotator cuf repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Focused Electrohydraulic Shockwaves for wound healing

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Inserting a bupivicaine-collagen implant into a surgical wound for postoperative analgesia

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation